Nothing Special   »   [go: up one dir, main page]

HK1248601A1 - 作為激酶抑制劑的嘧啶衍生物及其治療應用 - Google Patents

作為激酶抑制劑的嘧啶衍生物及其治療應用

Info

Publication number
HK1248601A1
HK1248601A1 HK18108612.1A HK18108612A HK1248601A1 HK 1248601 A1 HK1248601 A1 HK 1248601A1 HK 18108612 A HK18108612 A HK 18108612A HK 1248601 A1 HK1248601 A1 HK 1248601A1
Authority
HK
Hong Kong
Prior art keywords
kinase inhibitors
pyrimidine derivatives
therapeutical applications
therapeutical
applications
Prior art date
Application number
HK18108612.1A
Other languages
English (en)
Inventor
Chunlin Tao
Qinwei Wang
Laxman Nallan
David Ho
Tulay Polat
Forrest Arp
Paul Weingarten
Original Assignee
Nantbioscience Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nantbioscience Inc filed Critical Nantbioscience Inc
Publication of HK1248601A1 publication Critical patent/HK1248601A1/zh

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
HK18108612.1A 2015-02-27 2018-07-03 作為激酶抑制劑的嘧啶衍生物及其治療應用 HK1248601A1 (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2015/018085 WO2016137506A1 (en) 2015-02-27 2015-02-27 Pyrimidine derivatives as kinase inhibitors and their therapeutical applications

Publications (1)

Publication Number Publication Date
HK1248601A1 true HK1248601A1 (zh) 2018-10-19

Family

ID=56789187

Family Applications (2)

Application Number Title Priority Date Filing Date
HK18108611.2A HK1248600B (zh) 2015-02-27 2018-07-03 作為激酶抑制劑的嘧啶衍生物及其治療應用
HK18108612.1A HK1248601A1 (zh) 2015-02-27 2018-07-03 作為激酶抑制劑的嘧啶衍生物及其治療應用

Family Applications Before (1)

Application Number Title Priority Date Filing Date
HK18108611.2A HK1248600B (zh) 2015-02-27 2018-07-03 作為激酶抑制劑的嘧啶衍生物及其治療應用

Country Status (13)

Country Link
US (2) US10766879B2 (zh)
EP (2) EP3261637B1 (zh)
JP (2) JP6444525B2 (zh)
KR (2) KR20170122782A (zh)
CN (2) CN107708690B (zh)
AU (2) AU2015383881B2 (zh)
BR (2) BR112017018183A2 (zh)
CA (2) CA2977764C (zh)
ES (1) ES2746007T3 (zh)
HK (2) HK1248600B (zh)
IL (2) IL254152B (zh)
RU (2) RU2701188C2 (zh)
WO (2) WO2016137506A1 (zh)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2977764C (en) * 2015-02-27 2021-11-09 Nantbioscience, Inc. Pyrimidine derivatives as kinase inhibitors and their therapeutical applications
CN108530361A (zh) * 2018-05-17 2018-09-14 重庆医药高等专科学校 一种5-[2-(3,5-二甲氧基苯基)乙基]-1h-吡唑-3-胺的合成工艺
CN113354599B (zh) * 2021-08-09 2021-10-26 长沙康鹏医药有限公司 尼达尼布关键中间体的制备方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5916596A (en) 1993-02-22 1999-06-29 Vivorx Pharmaceuticals, Inc. Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
US6096331A (en) 1993-02-22 2000-08-01 Vivorx Pharmaceuticals, Inc. Methods and compositions useful for administration of chemotherapeutic agents
US6537579B1 (en) 1993-02-22 2003-03-25 American Bioscience, Inc. Compositions and methods for administration of pharmacologically active compounds
EP2270006A1 (en) * 2002-08-08 2011-01-05 Amgen, Inc Pyridazine derivatives useful as vanilloid receptor ligands
CA2488739A1 (en) * 2002-08-30 2004-03-11 Eisai Co., Ltd. Nitrogen-containing aromatic derivatives
US8013153B2 (en) * 2006-03-23 2011-09-06 Janssen Pharmaceutica, N.V. Substituted pyrimidine kinase inhibitors
WO2008128231A1 (en) * 2007-04-16 2008-10-23 Hutchison Medipharma Enterprises Limited Pyrimidine derivatives
JO3265B1 (ar) 2008-12-09 2018-09-16 Novartis Ag مثبطات بيريديلوكسى اندولات vegf-r2 واستخدامها لعلاج المرض
UY32351A (es) * 2008-12-22 2010-07-30 Astrazeneca Ab Compuestos de pirimidinil indol para uso como inhibidores de atr
EP2451811A1 (en) 2009-05-27 2012-05-16 F. Hoffmann-La Roche AG Bicyclic indole-pyrimidine pi3k inhibitor compounds selective for p110 delta, and methods of use
SG181961A1 (en) * 2009-12-25 2012-08-30 Mochida Pharm Co Ltd Novel 3-hydroxy-5-arylisothiazole derivative
WO2014071378A1 (en) * 2012-11-05 2014-05-08 Nant Holdings Ip, Llc Substituted indol-5-ol derivatives and their therapeutical applications
CN105377261B (zh) * 2013-03-15 2017-12-15 南特生物科学公司 取代的吲哚‑5‑酚衍生物和它们的治疗应用
WO2014183300A1 (en) * 2013-05-17 2014-11-20 Suzhou Vivotide Biotechnologies Co., Ltd. Vegfr tyrosine kinase inhibitors
CA2977764C (en) 2015-02-27 2021-11-09 Nantbioscience, Inc. Pyrimidine derivatives as kinase inhibitors and their therapeutical applications

Also Published As

Publication number Publication date
IL254152A0 (en) 2017-10-31
AU2015383881B2 (en) 2021-01-28
RU2017133448A3 (zh) 2019-09-23
EP3261637B1 (en) 2021-05-26
RU2017133419A3 (zh) 2019-03-27
AU2015383881A1 (en) 2017-09-07
HK1248600B (zh) 2020-04-24
KR102008082B1 (ko) 2019-08-06
EP3261637A1 (en) 2018-01-03
RU2701188C2 (ru) 2019-09-25
EP3261638A1 (en) 2018-01-03
US10766879B2 (en) 2020-09-08
JP6442071B2 (ja) 2018-12-19
AU2016224969B2 (en) 2019-10-31
US20180215734A1 (en) 2018-08-02
WO2016138527A1 (en) 2016-09-01
EP3261638A4 (en) 2018-08-08
IL254152B (en) 2021-03-25
IL254151A0 (en) 2017-10-31
JP2018506564A (ja) 2018-03-08
CN107635553B (zh) 2020-08-14
BR112017018183A2 (pt) 2018-07-24
CA2977810A1 (en) 2016-09-01
WO2016137506A1 (en) 2016-09-01
RU2017133419A (ru) 2019-03-27
AU2016224969A1 (en) 2017-09-07
EP3261637A4 (en) 2018-08-08
RU2017133448A (ru) 2019-03-27
US20180155327A1 (en) 2018-06-07
CN107708690A (zh) 2018-02-16
JP6444525B2 (ja) 2018-12-26
CA2977764C (en) 2021-11-09
BR112017018409A2 (pt) 2018-07-17
RU2718915C2 (ru) 2020-04-15
KR20170122781A (ko) 2017-11-06
KR20170122782A (ko) 2017-11-06
EP3261638B1 (en) 2019-05-08
CA2977764A1 (en) 2016-09-01
ES2746007T3 (es) 2020-03-04
JP2018506565A (ja) 2018-03-08
CN107708690B (zh) 2021-09-14
CN107635553A (zh) 2018-01-26

Similar Documents

Publication Publication Date Title
HK1256535A1 (zh) 吡唑嘧啶衍生物及其用途
IL268614B (en) Aminotriazolopyridines as kinase inhibitors
AP2016009487A0 (en) Novel pyrazolo pyrimidine derivatives and their use as malt1 inhibitors
IL259150B (en) Pyrimidine derivative and use thereof
SG10201913927VA (en) Kinase inhibitors and uses thereof
ZA201708568B (en) Pyrimidine derivatives as btk inhibitors and uses thereof
IL274207B (en) Aminoimidazopyridazines as kinase inhibitors
HK1250028A1 (zh) 2-苯基-6-咪唑基-吡啶-4-甲酰胺衍生物及其作為eaat3抑制劑的用途
HK1248601A1 (zh) 作為激酶抑制劑的嘧啶衍生物及其治療應用
EP3284746A4 (en) Preparation and use of kinase inhibitor
IL258690A (en) Pyridone derivatives and their use as kinase inhibitors
EP3347357A4 (en) HETEROCYCLIC KINASEINHIBITORS OF THE TEC FAMILY
GB201705201D0 (en) Novel compounds and their use as kinase inhibitors
GB201609580D0 (en) Novel compounds and their use as kinase inhibitors
GB201509381D0 (en) Novel compounds and their use as kinase inhibitors
GB201505460D0 (en) Novel compounds and their use as kinase inhibitors
GB201519382D0 (en) Kinase inhibitors
GB201519381D0 (en) Kinase inhibitors
GB201514761D0 (en) Preparation and uses of pyrimidinone derivatives